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Abstract
Background: The prognosis of non-small-cell lung cancer (NSCLC) is poor yet mechanistic understanding and
therapeutic options remain limited. We investigated the biological and clinical significance of microRNA-130b and
its relationship with apoptosis in NSCLC.
Methods: The level of microRNA-130b in relationship with the expression of PPARγ, VEGF-A, BCL-2 and apoptosis were
analyzed in 91 lung cancer patient samples using immunohistochemistry and terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay on tissue microarrays. Gain and loss-of-function studies were performed to
investigate the effects of microRNA-130b, peroxisome proliferator-activated receptor γ (PPARγ) or vascular endothelial
growth factor-A (VEGF-A) on biological functions of lung cancer cells using in vitro and in vivo approaches.
Results: MicroRNA-130b up-regulation conferred unfavorable prognosis of lung cancer patients. Notably, microRNA-130b
targeted PPARγ and inhibiting microRNA-130b markedly repressed proliferation, invasion and metastasis of lung cancer
cells, leading to increased apoptosis. MicroRNA-130b-dependent biologic effects were due to suppression of PPARγ that
in turn activated BCL-2, the key mediator of anti-apoptosis. Administration of microRNA-130b mimic to mouse xenografts
promoted tumor growth. In vitro and in vivo, miR-130b enrichment associated with down-regulation of PPARγ,
up-regulation of VEGF-A and BCL-2, and decreased apoptosis.
Conclusions: The present study demonstrates that microRNA-130b promotes lung cancer progression via
PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis. Targeting microRNA-130b might have remarkable
therapeutic potential for lung cancer therapy.
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Background
Several microRNAs (miRNAs), such as miR-21, miR-152,
miR-148b and miR-208a, play critical roles in lung cancer
progression through modulating growth, apoptosis, me-
tastasis and invasion [1–4]. A recent study has identified
microRNA-130 (miR-130) as a contributor in mesenchy-
mal differentiation, hypoxic response modulation and
tumorigenesis in colorectal cancer [5]. MiR-130b has also
been documented in several other kinds of tumors, with
up-regulation in melanoma [6], but down-regulation in
endometrial cancer [7] and pituitary adenomas [8].
Peroxisome proliferator-activated receptor γ (PPARγ),
acting as a tumor suppressor, exerts an essential role in
modulating tumor proliferation, differentiation, apop-
tosis and invasion [9–11]. Combined treatment with the
cyclo-oxygenase-2 (Cox-2) inhibitor niflumic acid and
PPARγ ligand ciglitazone induces endoplasmic reticulum
stress/caspase-8-mediated apoptosis in human lung can-
cer cells [12]. Treatment of human NSCLC lines with
PPARγ ligands results in growth arrest, loss of capacity
and induction of apoptosis [13]. Additionally, PPAR-
response element (PPRE) has been identified in the
human vascular endothelial growth factor-A (VEGF-A)
promoter region [14] and PPARγ ligands have been
* Correspondence: xiaoyanb@126.com; xiaoyanb@smu.edu.cn
†Equal contributors
1State Key Laboratory for Organ Failure Research, Division of Nephrology,
Nanfang Hospital, Southern Medical University, Guangzhou 510515,
Guangdong, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tian et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:105 
DOI 10.1186/s13046-016-0382-3
documented to down-regulate VEGF-A expression in
prostate cancer [15]. VEGF-A up-regulation has been
implicated in lung carcinogenesis [16] and correlates
with apoptosis by driving the expression of BAX [17].
However whether VEGF-A interacts with BCL-2, a clas-
sical anti-apoptotic gene, in modulating lung cancer cell
apoptosis remains unclear.
Studies have revealed that miR-130b promotes tumor
aggressiveness by suppressing PPARγ but promotes
VEGF-A expression and epithelial to mesenchymal transi-
tion (EMT) in hepatocellular [18] and colorectal cancer
[5]. In terms of the correlations between PPARγ, VEGF-A
and apoptosis, we hypothesize that miR-130b suppresses
PPARγ and promotes lung cancer progression via VEGF-
A/BCL-2-mediated inhibition of apoptosis. We also inves-
tigated the correlation between miR-130b expression and
lung cancer patient’s prognosis and survival. Mechanisms
of miR-130b/PPARγ-mediated apoptosis and lung cancer
progression were also explored.
Methods
Patients and specimens
Total 91 NSCLC patients undergoing treatment in
Nanfang Hospital in Guangzhou China from 2012 to
2015 were selected. This study was specifically approved
by the Southern Medical University Ethnics Committee.
Informed consent was obtained from all individual par-
ticipants included in the study. The overall survival time
after tumor resection was 57.9 months (range 19–98
months). Specimens from these patients were obtained
from the Department of Pathology and the Department
of Thoracic Surgery in Nanfang Hospital. Thirty-six snap
frozen fresh tumor samples and matched normal lung
tissues (10 cm from the tumor) obtained from among
the 91 specimens were also available for the study. Clin-
ical pathologic characteristics of the patients were based
on the World Health Organization criteria [19], as was
described in Table 1.
Total RNA from tissues of lung cancer patients and
healthy controls was extracted using Trizol Reagent (Invi-
trogen, Carlsbad, CA). The synthetic oligonucleotide (3’-
UUUCAUGUCGAUUUCAUUUCAUG-5’) non-existent in
humans was spiked-in for quality control before miRNAs
extraction according to the manufacturer’s instructions.
The thermal cycle (Ct) values for a serial dilution of these
miRNAs were assessed. All experiments were repeated in
triplicate.
Immunolabeling
Tissue microarray construction, immunohistochemical
staining and immunofluorescence co-labeling were
carried out according to previously published procedures
[20]. Briefly, samples were stained with the antibodies to
PPARγ, VEGF-A and BCL-2 (Abcam, Cambridge)
followed by EnVision/HRP Kit (Dako, Carpinteria, CA)
and imaged with a BX51 light microscope (Olympus,
Tokyo). The staining intensity was scored according to
previously procedures [21].
Cell culture studies
A549 (adenocarcinoma) and H520 (squamous cell car-
cinoma) lung cancer cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and
maintained in RPMI 1640 supplemented with 1 %
penicillin/streptomycin and 10 % fetal bovine serum
(FBS) in 5 % CO2, 37°C cell culture incubator.
Transfection of miRNA inhibitor and small interfering RNA
MiR-130b inhibitor (anti-M), miR-130b mimic, or the
appropriate negative controls of miRNA inhibitor (anti-
MC) and miRNA mimic were purchased from Gene-
Pharma (Shanghai, China). Anti-M and anti-MC were
transfected at a final concentration of 50–100 nM in the
cells using HiPerFect Transfection Reagent (Qiagen,
Table 1 Clinicopathologic characteristics of patients with lung
cancer
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Hilden, Germany) according to the manufacturer’s rec-
ommendations. Expression of PPARγ and VEGF-A were
knocked down with small interfering RNA (siRNA)
duplexes using Oligofectamine (Invitrogen, Carlsbad,
CA). The target sequences for PPARγ and VEGF-A
mRNA were shown in Table 2. Non-targeting siRNA
pool (D-001206-13-05; Dharmacon, Fisher Scientific,
Pittsburgh, PA) was used as a negative control. Cells
were harvested 72 hours post transfection for analysis.
Luciferase reporter assay
The predicted 3'-untranslated region (UTR) sequence of
PPARγ and BCL-2 interacting with miR-130b and
VEGF-A, respectively, and mutated sequences within the
predicted target sites were synthesized and inserted into
the pRL-TK control vector (Promega, Madison, WI).
H520 cells transfected with 120 ng anti-miR-130b,
VEGF-A siRNA or negative controls, followed by co-
transfection with 30 ng of the wild-type or mutant 3'-
UTR of the mRNA of PPARγ or BCL-2 using 0.45 μL of
Fugene (Promega, Madison, WI). Luciferase assay was
carried out using Dual-Luciferase Assay System (Pro-
mega, Madison, WI). Data were normalized by the ratio
of firefly and Renilla luciferase activities measured at
48 h post-transfection.
Drug treatment
VEGF-A inhibitor (bevacizumab, 2.5 μM) and PPARγ in-
hibitor, GW9662 (20 μM, Sigma-Aldrich, St. Louis, MO)
were used to treat A549 and H520 cells for 72 h and
harvested for further analysis.
Cell proliferation assay
Cell proliferation analysis was performed in triplicate
using a CellTiter 96 Non-Radioactive Cell Proliferation
Assay Kit (Promega, Madison, WI) following the manu-
facturer’s protocols.
Cell migration assay
Cells (1.0 × 106 cells/ml) in serum-free medium were
added to the top chamber of 24-well transwell plates
(8 mm pore size; Corning Star, Cambridge, MA) and
600 μl of complete medium with 10 % FBS into the
bottom chamber. The assembled chamber was incubated
at 37 °C in a humidified, 5 % CO2 cell culture incubator
for 24 h, fixed with 10 % formalin and stained with
hematoxylin and eosin staining for visualization.
Cell invasion assay
Cells (5.0 × 104 cells/mL) were plated in 6-well plates
and grown to over 90 % confluence. The monolayer of
cells was scratched with a 200 μL pipette tip to create a
wound gap, and treated with miR-130b inhibitor, siRNAs
of PPARγ or VEGF-A, and control (0.1 % DMSO) at in-
dicated time points. The same visual field was photo-
graphed using BX41 light microscope (10× objective)
throughout the experiment. Wound closure was calcu-
lated as follows: Wound closure (%) = Gap (T-T0)/
GapT0 × 100 % (where T is the treatment time and T0
is the time that the wound was induced).
In vitro plate-colony formation assay
Cells (200 cells/well) were plated in a six-well tissue
culture plate and cultured for two weeks. Colonies
with ≥50 cells were counted and plate colony forma-
tion efficiency was evaluated according to the follow-
ing formula: (number of colonies/number of cells
inoculated) × 100 %. Triplicate samples from each
group of cells were examined and colonies were
counted by two individuals (XL and JG).
Apoptosis assay and cell cycle analysis using flow
cytometry
Fixed cells were stained with the Annexin V-PE/7-
AAD apoptosis kit (559763, BD Biosciences, Franklin
Lakes, NJ) and apoptosis was evaluated by examining
the percentage of apoptotic cells. Data acquisition and
analysis were performed using Cell Quest software via
a FACScan flow cytometer (BD Biosciences, Franklin
Lakes, NJ). The results were analyzed with the ModFit 3.0
software (Verity Software House, Topsham, ME). All ex-
periments were repeated in triplicate.
TUNEL assay
Cells subjected to siRNA transfection or untreated cells
were fixed with 4 % paraformaldehyde and detected
using terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay with an Apoptag Peroxidase
in Situ Apoptosis Detection kit (Chemicon International,
Temecula, CA) as described previously [22].
qRT-PCR analysis
qRT-PCR analysis was carried in triplicate with Power
PCR SYBR Green Master Mix (Applied Biosystems,
Carlsbad, CA) using the ABI PRISM 7500 FAST Real-
TIME PCR System (Applied Biosystems, Carlsbad, CA)
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with results normalized to U6 or β-actin expression. The
relative expression was calculated using the ΔΔCT
method. Primer sequences used in qRT-PCR were listed
in Table 3.
The specific miR-130b miScript Primer Assays (Qiagen,
Hilden, Germany) were used for miRNA expression ana-
lysis. RNA was reverse transcribed using miRScript PCR
System and analyzed by qRT-PCR with the miScript SYBR
Green PCR Kit. MiR-130b levels were calculated as fold
change (2-ΔΔCT) with respect to normal controls. The
mean value of miR-130b expression in tumor tissues was
calibrated to the levels detected in normal control tissues.
Target-specific reverse transcription and Taqman micro-
RNA assays were performed using the Hairpin-itTM
miRNA qPCR Quantitation Kit (GenePharma, Suzhou)
according to the protocol. The reactions were performed
using the ABI PRISM 7500 FAST Real-TIME PCR System
(Applied Biosystems, Carlsbad, CA). The relative expres-
sion of miR-130b was shown as fold difference relative to
U6. The average value between 0.5 to 1.0 was regarded as
miR-130b low and the value between 1.0 to 1.6 as miR-
130b high. The 2-ΔΔCt method was used to calculate the
relative expression. All experiments were performed in
triplicate.
Western blot analysis and immunoprecipitation
Cell lysates from each experimental group were sepa-
rated in parallel on two 10 % denaturing SDS-PAGE
gels, transferred onto nitrocellulose membranes, blocked
with 5 % non-fat milk in 0.1 % tris buffered saline with
Tween-20 (TBST), and probed with antibodies to
PPARγ, VEGF-A, and BCL-2, followed by incubation
with appropriate secondary antibodies. The probed
membrane was exposed and protein bands were visual-
ized on X-ray films (Kodak X-OMAT BT, Rochester,
NY). Immunoprecipitation was performed as previously
described [23].
In Vivo Studies of Tumorigenicity
Male balb/c nude mice were kept in the Animal Center
of Nanfang Hospital, Guangzhou, China according to
the policies of the Committee for Animal Usage. To
evaluate in vivo tumor growth, A549 cells with miR-
130b mimic or appropriate controls (2 ng/mm3) were
injected subcutaneously into the left flanks of ten mice.
Thirty days after the injection, mice were euthanized
and tumor growth was evaluated. Tumor volume (mm3)
was calculated as (W2 × L)/2. Immunohistochemical
staining for PPARγ, VEGF-A and BCL-2 were performed
on mouse tissue specimens according to the previously
mentioned method [21].
Statistical analysis
Data are expressed as mean ± standard deviation (SD)
values. Correlations between expressions of miR-130b
and PPARγ, VEGF-A and BCL-2 and lung cancer pa-
tients’ clinical pathological characteristics were analyzed
using two-sided Fisher’s Exact Test. Pearson Correlation
Analysis and Independent-Samples T Test were used to
evaluate the correlation and significance between the ex-
pression of VEGF-A and PPARγ or BCL-2. Overall pa-
tient survival was calculated from the time of surgery to
the time of death or to the time of last follow-up, at
which point the data were censored. Kaplan-Meier
method and the log-rank test were used to evaluate the
difference between high and low miR-130b expression
subgroups and the overall survival curves were gener-
ated. SPSS 13.0 (SPSS Inc., Chicago, IL) was used for all
statistical analysis. A p < 0.05 was regarded as statistically
significant.
Results
High miR-130b expression confers unfavorable prognosis
of lung cancer patients
To investigate whether miR-130b expression predicts
patients’ prognosis, we examined miR-130b expression
in tissues of lung cancer patients. We found increased
miR-130b expression in lung cancer tissues compared
with corresponding normal lungs. By qRT-PCR
(Fig. 1a), low level of miR-130b was detected in 46
cases and high miR-130b expression was found in 45
cases. In lung cancer tissues, high miR-130b level cor-
responded with low PPARγ, high VEGF-A and BCL-2,
and decreased apoptosis (Figs. 1b, c and d). Kaplan-
Meier survival analysis demonstrated that patients with
high miR-130b expression had a shorter overall survival
time compared to patients with low miR-130b expression
(Fig. 1e, 48.4 vs. 67.8 months, p < 0.001). Immunofluores-
cence co-labeling and Pearson correlation analysis (Fig. 2)
revealed that PPARγ expression negatively correlated with
VEGF-A (r = −0.351, p = 0.001), and VEGF-A positively
correlated with BCL-2 (r = 0.328, p = 0.002). MiR-130b
Table 3 Primer sets used in real time RT-PCR
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expression associated with differentiation (p = 0.002)
and TNM stage (p = 0.025) of lung cancer patients
(Table 4). These results suggested that miR-130b could
be used as a marker to predict lung cancer patients’
prognosis.
MiR-130b inhibition attenuates lung cancer cell
aggressiveness via PPARγ/VEGF-A/BCL-2-mediated
enhancement of apoptosis
To decipher whether miR-130b promotes lung cancer
progression and underlying mechanisms, we examined
the effect of miR-130b inhibitor on the biological fea-
tures of lung cancer cells and relationships with
apoptosis. Inhibition of miR-130b increased PPARγ
expression but decreased VEGF-A and BCL-2 as con-
firmed by immunofluorescence microscopy (Fig. 3a
and b). Compared with negative controls, anti-miR-
130b caused 23.7 % increase in the mRNA level of
PPARγ, but 47.3 % and 43.2 % reduction in VEGF-A
and BCL-2 as detected by qRT-PCR (Fig. 3c). Western
blot analysis demonstrated that anti-miR-130b in-
creased the level of PPARγ by 65.2 % but decreased
Fig. 1 High miR-130b expression confers unfavorable prognosis of lung cancer patients. a MiR-130b expression in lung cancer tissues. b MiR-130b
expression in relation to the expression of PPARγ, VEGF-A and BCL-2. c Representative TMA sections stained for PPARγ, VEGF-A and BCL-2
by immunohistochemistry (scale bar, 100 μm), and apoptosis by TUNEL assay (scale bar, 50 μm). d Correlations between miR-130b level
and PPARγ, VEGF-A, BCL-2 or apoptosis. e A shorter overall survival time in patients with high miR-130b. NL, normal lung; AD, adenocarcinoma; SQ,
squamous cell carcinoma; TUNEL, terminal deoxynucleotidyl transferase-mediated uridine 5’-triphosphate-biotin nick end labeling. *p < 0.05, #p < 0.001
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VEGF-A and BCL-2 by 60.8 % and 38.5 %, respect-
ively (Fig. 3d). To further demonstrate that miR-130b
targeted PPARγ in lung cancer cells, we investigated
whether miR-130b interacted with the 3’-UTR of
PPARγ mRNA using a dual-luciferase reporter assay.
As shown, miR-130b depletion led to a significant in-
crease in the luciferase activity of the wild-type re-
porter but not the mutant (Fig. 3e). A significantly
slower proliferation rate was observed in lung cancer
cells treated with anti-miR-130b compared with con-
trols (Fig. 3f ). MiR-130b depletion inhibited the abil-
ity of cells to invade (Fig. 3g), migrate (Fig. 3h) and
form colonies (Fig. 3i). Anti-miR-130b caused 1.48-
fold increase in the number of apoptotic cells com-
pared with control cells by flow cytometric analysis
(Fig. 3j). TUNEL assay revealed that miR-130b
abrogation significantly enhanced apoptosis and
caused 52.6 % increase in the apoptotic rate (Fig. 3k).
Conversely, miR-130b mimic had the opposite effects
(Additional file 1: Supplementary Figure). These
results collectively suggested that miR-130b inhibition
decreased lung cancer cell aggressiveness via PPARγ/
VEGF-A/BCL-2-mediated enhancement of apoptosis.
PPARγ silencing enhances lung cancer cell aggressiveness
via VEGF-A/BCL-2-mediated suppression of apoptosis
Next we knocked down PPARγ in lung cancer cells to
investigate whether PPARγ mediated apoptosis through
the VEGF-A/BCL-2 pathway and whether PPARγ had
feedback regulation of miR-130b expression. We found
that PPARγ silencing increased the expression of VEGF-
A and BCL-2 as demonstrated by immunofluorescence
Fig. 2 The expression of VEGF-A in correlation with PPARγ and BCL-2. a Representative sections co-labeled for PPARγ (green) and VEGF-A (red)
and b the quantification analysis. c Negative correlation between PPARγ and VEGF-A expression. d Representative sections co-labeled for VEGF-A
(red) and BCL-2 (green) and e the quantification analysis. f Positive correlation between VEGF-A and BCL-2. Scale bar, 50 μm. Each bar represents
the mean ± SD. Results are representative of three independent experiments. *p < 0.05, #p < 0.001
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microscopy (Fig. 4a and b). Compared with negative
controls, PPARγ siRNAs (#1 and #2) decreased the
mRNA level of PPARγ (46.1 and 39.5 %), but increased
VEGF-A (23.8 and 21.3 %) and BCL-2 (12.1 and 11.3 %),
respectively, as shown by qRT-PCR (Fig. 4c). PPARγ siR-
NAs (#1 and #2) decreased the protein level of PPARγ
(87.4 and 89.8 %), but increased VEGF-A (89.9 and
88.7 %) and BCL-2 (86.8 and 85.9 %), respectively, as de-
tected by Western blot analysis (Fig. 4d). A significantly
faster proliferation rate and more Ki-67 positive cells
were observed in PPARγ-silenced cells as compared with
control cells (Fig. 4e and f). PPARγ silencing promoted
the invasion (Fig. 4g) and migration ability (Fig. 4h) of
lung cancer cells with increased ability to form colonies
(Fig. 4i). PPARγ siRNAs caused significant decrease in
the number of apoptotic cells (8.8 and 8.6 %) compared
with control cells (11.9 %) by flow cytometric analysis
(Fig. 4j). PPARγ silencing caused 58.3 and 54.7 %
decrease in the cell apoptotic rate by TUNEL assay
(Fig. 4k). However, PPARγ siRNAs had no effects on the
expression level of miR-130b (Fig. 4l). These results
suggested that PPARγ depletion promoted the aggres-
siveness of lung cancer cells through VEGF-A/BCL-2-
mediated suppression of apoptosis. However, PPARγ did
not have feedback regulation on miR-130b.
Knockdown of VEGF-A reduces lung cancer cell
aggressiveness via BCL-2-mediated activation of
apoptosis in vitro
To further investigate whether VEGF-A induced cell
apoptosis via BCL-2 inhibition, VEGF-A siRNAs were
used to knock down the expression of VEGF-A. Down-
stream gene expressions and biological features of cells
were examined. Immunofluorescence microscopy
revealed that VEGF-A siRNAs decreased the expression
of BCL-2 and the two molecules co-localized with each
other (arrowheads) (Fig. 5a). Compared with negative
control cells, VEGF-A siRNAs (#1 and #2) decreased the
mRNA level of VEGF-A (28.3 and 29.2 %) and BCL-2
(65.6 and 63.3 %), respectively, by qRT-PCR (Fig. 5b).
VEGF-A siRNAs (#1 and #2) decreased the protein level
of VEGF-A (63.8 and 91.4 %) and BCL-2 (88.1 and
60.8 %), respectively, by Western blot analysis (Fig. 5c).
VEGF-A siRNA led to a significant decrease in the lucif-
erase activity of wt 3'-UTR of BCL-2 (Fig. 5d). Further-
more,VEGF-A siRNAs slowed cell growth (Fig. 5e and f),
reduced the ability of cells to migrate (Fig. 5g), invade
(Fig. 5h) and form colonies (Fig. 5i). VEGF-A siRNAs
caused significant increase in the number of apoptotic
cells (17.0 and 17.3 %) as detected by flow cytometric ana-
lysis (Fig. 5j) and 30.5 and 28.1 % increase in the apoptotic
rate by TUNEL assay (Fig. 5k). However,VEGF-A siRNAs
had no effects on miR-130b expression (Fig. 5l). These re-
sults demonstrated that VEGF-A silencing induced cell
apoptosis via inhibition of BCL-2. However, VEGF-A had
no feedback regulation on miR-130b in lung cancer cells.
PPARγ antagonism abolishes the effect of miR-130b
inhibition on VEGF-A/BCL-2-mediated apoptosis
To further explore whether miR-130b targets PPARγ in
mediating apoptosis, we treated lung cancer cells with
PPARγ antagonist GW9662 and examined the down-
stream effects. Western blot analysis demonstrated that
anti-miR-130b up-regulated the expression level of
PPARγ but down-regulated VEGF-A and BCL-2.
GW9662 abolished the effect of miR-130b inhibition on
the expression of VEGF-A and BCL-2 (Fig. 6a). Treat-
ment with VEGF-A inhibitor bevacizumab (2.5 μM)
down-regulated the expression of BCL-2 in a time-
(Fig. 6b) and dose-dependent manner (Fig. 6c). Immuno-
precipitation analysis revealed that bevacizumab signifi-
cantly inhibited the interaction between PPARγ and
VEGF-A upon miR-130b inhibition (Fig. 6d), suggesting
VEGF-A acted as the downstream of PPARγ in mediat-
ing the cascade of events. Further studies also demon-
strated that VEGF-A interacted with BCL-2 upon
PPARγ inhibition (Fig. 6e). Flow cytometric analysis
Table 4 Correlation between MiR-130b and patient
clinicopathological characteristics
Items MiR-130b (N = 91) p
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(Fig. 6f, upper panels) and the TUNEL assay (Fig. 6f,
middle panels) demonstrated that PPARγ antagonist
GW9662 attenuated the effect of miR-130b inhibition on
VEGF-A/BCL-2-mediated apoptosis (Fig. 6f, lower
panels). Taken together, these results suggested that
PPARγ functioned as a critical regulator in miR-130b
mediated lung cancer apoptosis through the VEGF-A/
BCL-2 pathway.
Fig. 3 MiR-130b inhibition attenuates lung cancer cell aggressiveness via PPARγ/VEGF-A/BCL-2-mediated enhancement of apoptosis. a Representative
images of A549 cells treated with anti-miR-130b and co-labeled for PPARγ (green) and VEGF-A (red) (scale bar, 50 μm). b Representative images of
A549 cells treated with anti-miR-130b and labeled for BCL-2 (green) (scale bar, 50 μm). c and d Anti-miR-130b increased PPARγ, but decreased VEGF-A
and BCL-2. e MiR-130b and its putative binding sequence in the PPARγ 3'-UTR. The mutant PPARγ binding site was generated in the complementary
site for the seed region of miR-130b. Anti-miR-130b caused a significant increase in the luciferase activity of wt 3'-UTR of PPARγ. f A slower proliferation
rate in cells treated with anti-miR-130b compared with controls. g Decreased number of invaded cells with anti-miR-130b treatment (scale bar,
100 μm). h Shorter migrated distance in cells treated with anti-miR-130b at indicated time points. i Decreased colonies in cells treated with anti-miR-
130b at 48 hours time point. j Increased apoptotic cells treated with anti-miR-130b compared with controls. k Increased apoptotic rate in cells treated
with anti-miR-130b (scale bar, 50 μm). Anti-MC: anti-miR-130b control; anti-M: anti-miR-130b; TUNEL, terminal deoxynucleotidyl transferase-mediated
uridine 5’-triphosphate-biotin nick end labeling; UTR, untranslated region; wt, wild type; mt, mutant type. Each bar represents the mean ± SD. Results
are representative of three independent experiments. *p < 0.05, #p < 0.001
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MiR-130b promotes tumor growth and suppresses
apoptosis via PPARγ/VEGF-A/BCL-2 signaling in mouse
xenografts
To investigate the effect of miR-130b on tumor
growth in vivo, miR-130b mimic or controls was
injected subcutaneously into the mouse. We found
that miR-130b mimic significantly increased the
tumor volume of A549 mouse xenografts compared
with controls in one month time (Fig. 7a and b).
MiR-130b mimic decreased the protein level of
Fig. 4 PPARγ silencing enhances lung cancer cell aggressiveness via VEGF-A/BCL-2-mediated suppression of apoptosis. a Representative images of
A549 cells treated with PPARγ siRNAs and co-stained for PPARγ (green) and VEGF-A (red) (scale bar, 50 μm). b Representative images of A549 cells
treated with PPARγ siRNAs and stained for BCL-2 (green) (scale bar, 50 μm). c and d PPARγ siRNAs (#1 and #2) decreased PPARγ, but increased
VEGF-A and BCL-2, respectively. e A faster proliferation rate in PPARγ-silenced cells compared with controls. f More Ki-67 positive proliferative cells
(green) in PPARγ-silenced cells (scale bar, 100 μm). g Increased number of invaded PPARγ-silenced cells compared with controls (scale bar,
100 μm). h Longer migrated distance in PPARγ-silenced cells at indicated time points. i Increased colonies in PPARγ-silenced cells at 48 hours time
point. j Decreased apoptotic cells (8.8 and 8.6 %) compared with controls (11.9 %). k Decreased apoptotic rate in PPARγ-silenced cells (scale bar,
100 μm). l No effect of PPARγ siRNAs on the level of miR-130b. NT siRNA: non-targeting small interference RNA; TUNEL, terminal deoxynucleotidyl
transferase-mediated uridine 5’-triphosphate-biotin nick end labeling. Each bar represents the mean ± SD. Results are representative of
three independent experiments. *p < 0.05, #p < 0.001
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PPARγ by 51.7 %, but increased VEGF-A and BCL-2
by 41.3 and 52.6 %, respectively, confirmed by immu-
nohistochemistry (Fig. 7c) and quantification of the
staining intensity (Fig. 7d). MiR-130b mimic reduced
the apoptotic rate by 52.6 % (Fig. 7e), decreased
PPARγ mRNA level by 53.3 %, increased VEGF-A
and BCL-2 by 62.8 and 49.3 %, respectively, as de-
tected by qRT-PCR (Fig. 7f ). MiR-130b mimic de-
creased PPARγ protein level by 87.2 %, but increased
VEGF-A and BCL-2 by 96.4 and 90.1 %, respectively,
by Western blot analysis (Fig. 7g). These data con-
firmed the in vitro findings and further supported the
Fig. 5 Knockdown of VEGF-A reduces lung cancer cell aggressiveness via BCL-2-mediated activation of apoptosis in vitro. a Representative images
stained for VEGF-A (red) and BCL-2 (green) and co-localization (yellow, arrowheads) (scale bar, 50 μm). b and c VEGF-A siRNAs (#1 or 2) decreased
VEGF-A and BCL-2, respectively. d VEGF-A siRNAs caused a significant decrease in the luciferase activity of wt 3'-UTR of BCL-2. e A slower proliferation rate in
cells treated with VEGF-A siRNAs compared with controls. f Fewer Ki-67 positive cells in VEGF-A silenced cells compared with controls (scale bar, 100 μm). (g)
Decreased number of invaded cells with VEGF-A siRNAs (scale bar, 100 μm). (h) Shorter migrated distance in cells treated with VEGF-A siRNAs at indicated time
points. (i) Decreased colonies in VEGF-A silenced cells at 48 hours time point. j Increased apoptotic cells (17.0 and 17.3 %) compared with controls (11.9 %).
k Increased apoptotic rate in VEGF-A silenced cells (scale bar, 50 μm). l No effect of VEGF-A siRNAs on the level of miR-130b. NT siRNA: non-targeting small
interference RNA. Each bar represents the mean± SD. Results are representative of three independent experiments. *p< 0.05, #p< 0.001
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notion that miR-130b promoted tumor growth and
suppressed apoptosis via PPARγ/VEGF-A/BCL-2
signaling.
Discussion
The present study indicates that miR-130b increases the
expression of VEGF-A and BCL-2 but suppresses PPARγ
Fig. 6 PPARγ antagonism dampens the effect of miR-130b inhibition on VEGF-A/BCL-2-mediated apoptosis. a Requirement of PPARγ in
miR-130b mediated expressions of VEGF-A and BCL-2. b Bevacizumab down-regulated BCL-2 in a time- and c dose-dependent manner.
d Interaction between PPARγ and VEGF-A by immunoprecipitation. e Interaction between VEGF-A and BCL-2 by immunoprecipitation.
f Apoptosis was increased by anti-miR-130b but decreased by GW9662. Attenuation of the effect of miR-130b inhibition on apoptosis by
GW9662. Scale bar, 100 μm. Anti-M: anti-miR-130b; bev.: bevacizumab; TUNEL, terminal deoxynucleotidyl transferase-mediated uridine
5’-triphosphate-biotin nick end labeling. Each bar represents the mean ± SD. Results are representative of three independent experiments.
*p < 0.05, #p < 0.001
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and apoptosis. Importantly, we demonstrate that VEGF-
A targets BCL-2 and promotes the aggressiveness of
lung cancer cells via BCL-2-mediated suppression of
apoptosis. These data highlight the critical role of
miR-130b in promoting lung cancer progression
through PPARγ/VEGF-A/BCL-2-mediated suppression
of apoptosis (Fig. 8). Another major finding of this
study is that PPARγ antagonist GW9662 attenuates
the effect of miR-130b inhibition on VEGF-A/BCL-2-
mediated apoptosis and downstream gene expressions.
Furthermore, immunoprecipitation demonstrates the
interaction between PPARγ and VEGF-A, supporting
the notion that miR-130b plays a critical role in regu-
lating lung cancer cell aggressiveness and apoptosis
through the PPARγ/VEGF-A axis. However, neither
PPARγ nor VEGF-A siRNAs had feedback regulatory
effects on the miR-130b expression. This suggests that
miR-130b acts as the upstream of the PPARγ/VEGF-
A axis in mediating apoptosis and downstream gene
expressions.
Fig. 7 MiR-130b promotes tumor growth and suppresses apoptosis via PPARγ/VEGF-A/BCL-2 signaling in A549 mouse xenograft. a and b Larger
tumor volume treated with miR-130b mimic compared with the control at day 30. c MiR-130b mimic decreased PPARγ and apoptosis, but increased
VEGF-A and BCL-2 in A549-generated xenografts by immunohistochemistry (upper panels) and TUNEL assay (lower panel). d Quantification analysis of
the staining intensity and e the apoptotic rate. f and g MiR-130b mimic decreased the level of PPARγ in A549-generated xenografts, but increased
VEGF-A and BCL-2. Scale bar, 50 μm. CTRL: control; TUNEL, terminal deoxynucleotidyl transferase-mediated uridine 5’-triphosphate-biotin nick end labeling.
Each bar represents the mean ± SD. Results are representative of three independent experiments. *p< 0.05, #p< 0.001
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Studies have demonstrated that miR-130b suppresses
migration and invasion of colorectal cancer cells through
downregulation of Integrin-β1 [24]. MiR-130b may pro-
mote hepatocellular carcinoma cell migration and inva-
sion by inhibiting PPARγ and subsequently inducing
EMT [18, 25]. MiR-130b also plays an important profi-
brotic role in skin fibrosis and enhances TGF-β signaling
through repression of PPARγ [26]. Moreover, varied ex-
pression levels of miR-130b have been found in endo-
metrial [27], gastric [28] and bladder [29] cancer
regulating different signaling molecules. We found that
miR-130b, by targeting PPARγ, promotes aggressiveness
through VEGF-A-mediated suppression of apoptosis in
lung cancer. These studies demonstrate that miR-130b
plays a role in regulating tumor progression.
Functionally, our data indicate that miR-130b not only
exhibits a potent oncogenic role, in agreement with other
recent reports [30], but also suppresses lung cancer cell
apoptosis through VEGF-A-mediated up-regulation of
BCL-2, the classical anti-apoptotic gene. In addition, knock-
ing down VEGF-A caused a significant reduction in BCL-2
protein level and decreased luciferase activity. These results
together suggest that VEGF-A interacts with BCL-2 in me-
diating lung cancer cell apoptosis. It has been demonstrated
that in wild-type p53 expressing cells, miR-130b directly
represses Zinc finger E-box-binding homeobox 1 (ZEB1),
opposing EMT and invasive phenotypes. However, in the
context of gain-of-function p53 mutations, mutant p53 trig-
gers EMT by indirectly inducing ZEB1 expression through
negative regulation of miR-130b [27]. Undoubtedly, miR-
130b exerts a critical function in regulating cell apoptotic
processes. Our results have revealed for the first time that
miR-130b, through up-regulating the BCL-2 signaling,
enhances lung cancer progression and inhibits cell apop-
tosis. Future studies exploring the significance of circulating
miR-130b in lung cancer development and progression
may provide possible evidences for early detection and
screening of lung cancer risk factors. Our results have
shown that miR-130b promotes lung cancer progression
through PPARγ/VEGF-A/BCL-2-mediated suppression of
apoptosis.
Lines of evidence have demonstrated the link between
miRNA dysregulation with malignant transformation in
a variety of cancers [31–33]. Previous report [34] and
our present results identify miR-130b as an important
signature in lung cancer. MiR-130b up-regulation has
been detected in lung adenocarcinoma and squamous
cell carcinoma and confers advanced tumor stage, poor
differentiation and unfavorable prognosis of lung cancer
patients. This is in line with other studies showing that
miR-130b up-regulation correlates with the clinical stage
of gastric [35] and esophageal carcinoma [30]. However,
we found that in lung cancer tissues, cases with high
miR-130b expression level did not correlate positively
with lymph node metastases and larger tumor size. We
assume that factors, like the tumor microenvironment
or other growth factors, also contributed to the lymph
node metastasis and growth of lung tumors. In addition,
this could also be in part due to the limited sample size
analyzed in the present study, which needs further inves-
tigations in expanded samples.
Conclusions
We demonstrate that miR-130b targets PPARγ and sup-
presses lung cancer cell apoptosis through the VEGF-A/
BCL-2 pathway. High miR-130b expression confers
Fig. 8 Schematic diagram of microRNA-130b in promoting lung cancer progression via PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis
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unfavorable prognosis of lung cancer patients. These
findings indicate clinical values of our study and that
miR-130b is a potential new therapeutic target for lung
cancer diagnosis and treatment.
Additional file
Additional file 1: MiR-130b mimic enhances lung cancer cell
aggressiveness via PPARγ/VEGF-A/BCL-2-mediated suppression of
apoptosis. (A) Representative images of A549 cells treated with miR-130b
mimic and co-labeled for PPARγ (green) and VEGF-A (red) (scale bar,
50 μm). (B) Representative images of A549 cells treated with miR-130b
mimic and labeled for BCL-2 (green) (scale bar, 50 μm). (C and D) MiR-130b
mimic decreased PPARγ, but increased VEGF-A and BCL-2. (E) MiR-130b
mimic caused a significant decrease in the luciferase activity of wt 3'-UTR of
PPARγ. (F) A faster proliferation rate in cells treated with miR-130b mimic
compared with controls. (G) Increased number of invaded cells with miR-
130b mimic treatment (scale bar, 100 μm). (H) Longer migrated distance in
cells treated with miR-130b mimic at indicated time points. (I) Increased
colonies in cells treated with miR-130b mimic at 48 hours time point. (J)
Decreased apoptotic cells treated with miR-130b mimic compared with
controls. (K) Decreased apoptotic rate in cells treated with miR-130b mimic
(scale bar, 50 μm). NC: normal control; miR-NC: miR-130b control; miR-
130bm: miR-130b mimic; TUNEL, terminal deoxynucleotidyl transferase-me-
diated uridine 5’-triphosphate-biotin nick end labeling. Each bar represents the
mean ± SD. Results are representative of three independent experiments. *p <
0.05, #p < 0.001. (DOC 2779 kb)
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